Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.98 |
| ▸ | BCHE | P06276 | 15/20 | 0.64 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tianeptine SCHEMBL3996165 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL49293 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Hydrochloric Acid SCHEMBL22664293 | 0.99 | NR1I2 (0.96) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29930593 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29470274 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL29877330 | 0.99 | NR1I2 (1.00) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL2894680 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL2897771 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL1231001 | 0.98 | NR1I2 (0.98) | NR1I2OPRM1DRD3OPRD1BCHE | |
| Tianeptine SCHEMBL20338621 | 0.97 | NR1I2 (0.96) | NR1I2OPRM1DRD3OPRD1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092802-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. | 2024-03-21 | — | — | US | disclosed |
| US-20230365519-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3116509-B1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | UNIV COLUMBIA (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022074587-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-04-07 | — | — | US | disclosed |
| US-10844027-B2 | Carboxylic diarylthiazepineamines as mu-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190084949-A1 | NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084949-A1 | NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190047970-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AS MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-02-14 | — | — | US | disclosed |
| US-10183919-B2 | Class of mu-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170217913-A1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217913-A1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170217913-A1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2017049158-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AS MU-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| EP-1752143-A1 | Novel uses for drugs targeting glutamine synthetase | NewThera (FR) | 2007-02-14 | — | — | EP | disclosed |
| EP-0239436-B1 | Tricyclic derivative, namely 5-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo[C,F] [1,2]-thiazepin-11-ylamino)-pentanoic acid, process for its preparation and medicines and medicines containing it | ADIR ET COMPAGNIE (FR) | 1990-06-20 | — | — | EP | disclosed |
| US-4766114-A | ANTIDEPRESSNATS | ADIR ET COMPAGNIE (FR) | 1988-08-23 | — | — | US | disclosed |
| EP-0239436-A1 | Tricyclic derivative, namely 5-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo[C,F] [1,2]-thiazepin-11-ylamino)-pentanoic acid, process for its preparation and medicines and medicines containing it | ADIR ET COMPAGNIE (FR) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092802-A1 | MU-OPIOID RECEPTOR AGONISTS AND USES THEREFOR | OPRL1, OPRM1, CDKL5 | NR1I2 224/4885OPRM1 2/4885DRD3 1002/4885 |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | NR1I2 516/4885OPRM1 224/4885DRD3 1663/4885 |
| US-10183919-B2 | Class of mu-opioid receptor agonists | OPRM1, OPRL1, OPRK1 | NR1I2 183/4885OPRM1 1/4885DRD3 240/4885 |
| US-20190047970-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AS MU-OPIOID RECEPTOR AGONISTS | OPRL1, OPRM1, OPRK1 | NR1I2 401/4885OPRM1 2/4885DRD3 130/4885 |
| US-20220106279-A1 | CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | NR1I2 183/4885OPRM1 1/4885DRD3 240/4885 |
| US-20190084949-A1 | NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | NR1I2 164/4885OPRM1 1/4885DRD3 227/4885 |
| US-20230365519-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | CDKL5, CDKL1, H1-5 | NR1I2 629/4885OPRM1 3626/4885DRD3 382/4885 |
| US-10844027-B2 | Carboxylic diarylthiazepineamines as mu-opioid receptor agonists | OPRL1, OPRM1, OPRK1 | NR1I2 401/4885OPRM1 2/4885DRD3 130/4885 |
| US-20170217913-A1 | A NEW CLASS OF MU-OPIOID RECEPTOR AGONISTS | OPRM1, OPRL1, OPRK1 | NR1I2 175/4885OPRM1 1/4885DRD3 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.